Literature DB >> 27300702

A Multiplatform Metabolomics Approach to Characterize Plasma Levels of Phenylalanine and Tyrosine in Phenylketonuria.

H Blasco1,2, C Veyrat-Durebex3,4, M Bertrand5, F Patin3,4, F Labarthe6,7, H Henique8, P Emond4, C R Andres3,4, C Antar3,4, C Landon5, L Nadal-Desbarats4, F Maillot7,8.   

Abstract

BACKGROUND: Different pathophysiological mechanisms have been described in phenylketonuria (PKU) but the indirect metabolic consequences of metabolic disorders caused by elevated Phe or low Tyr concentrations remain partially unknown. We used a multiplatform metabolomics approach to evaluate the metabolic signature associated with Phe and Tyr.
MATERIAL AND METHODS: We prospectively included 10 PKU adult patients and matched controls. We analysed the metabolome profile using GC-MS (urine), amino-acid analyzer (urine and plasma) and nuclear magnetic resonance spectroscopy (urine). We performed a multivariate analysis from the metabolome (after exclusion of Phe, Tyr and directly derived metabolites) to explain plasma Phe and Tyr concentrations, and the clinical status. Finally, we performed a univariate analysis of the most discriminant metabolites and we identified the associated metabolic pathways.
RESULTS: We obtained a metabolic pattern from 118 metabolites and we built excellent multivariate models to explain Phe, Tyr concentrations and PKU diagnosis. Common metabolites of these models were identified: Gln, Arg, succinate and alpha aminobutyric acid. Univariate analysis showed an inverse correlation between Arg, alpha aminobutyric acid and Phe and a positive correlation between Arg, succinate, Gln and Tyr (p < 0.0003). Thus, we highlighted the following pathways: Arg and Pro, Ala, Asp and Glu metabolism. DISCUSSION: We obtain a specific metabolic signature related to Tyr and Phe concentrations. We confirmed the involvement of different pathophysiological mechanisms previously described in PKU such as protein synthesis, energetic metabolism and oxidative stress. The metabolomics approach is relevant to explore PKU pathogenesis.

Entities:  

Keywords:  Biomarkers; Metabolomics; NMR; Phenylketonuria

Year:  2016        PMID: 27300702      PMCID: PMC5362559          DOI: 10.1007/8904_2016_568

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  43 in total

1.  Long-term safety and efficacy of sapropterin: the PKUDOS registry experience.

Authors:  Nicola Longo; Georgianne L Arnold; Gabriella Pridjian; Gregory M Enns; Can Ficicioglu; Susan Parker; Jessica L Cohen-Pfeffer
Journal:  Mol Genet Metab       Date:  2015-02-16       Impact factor: 4.797

2.  Characterization of alpha-amino-n-butyric acid correlations in sepsis.

Authors:  Carlo Chiarla; Ivo Giovannini; John H Siegel
Journal:  Transl Res       Date:  2011-07-18       Impact factor: 7.012

3.  Unknown pathomechanisms of renal impairment in PKU.

Authors:  Julia B Hennermann; Uwe Querfeld
Journal:  J Inherit Metab Dis       Date:  2013-09-17       Impact factor: 4.982

4.  Targeted metabolomic analysis of plasma samples for the diagnosis of inherited metabolic disorders.

Authors:  Hana Janečková; Karel Hron; Petr Wojtowicz; Eva Hlídková; Anna Barešová; David Friedecký; Lenka Zídková; Petr Hornik; Darina Behúlová; Dagmar Procházková; Hana Vinohradská; Karolína Pešková; Per Bruheim; Vratislav Smolka; Sylvie Sťastná; Tomáš Adam
Journal:  J Chromatogr A       Date:  2011-10-04       Impact factor: 4.759

Review 5.  Phenylketonuria Pathophysiology: on the Role of Metabolic Alterations.

Authors:  Patrícia Fernanda Schuck; Fernanda Malgarin; José Henrique Cararo; Fabiola Cardoso; Emilio Luiz Streck; Gustavo Costa Ferreira
Journal:  Aging Dis       Date:  2015-10-01       Impact factor: 6.745

6.  Neurocognitive evidence for revision of treatment targets and guidelines for phenylketonuria.

Authors:  Rianne Jahja; Stephan C J Huijbregts; Leo M J de Sonneville; Jaap J van der Meere; Francjan J van Spronsen
Journal:  J Pediatr       Date:  2014-01-30       Impact factor: 4.406

Review 7.  Executive function in early-treated phenylketonuria: profile and underlying mechanisms.

Authors:  Shawn E Christ; Stephan C J Huijbregts; Leo M J de Sonneville; Desirée A White
Journal:  Mol Genet Metab       Date:  2010       Impact factor: 4.797

8.  Early dietary treated patients with phenylketonuria can achieve normal growth and body composition.

Authors:  Júlio C Rocha; Francjan J van Spronsen; Manuela F Almeida; Elisabete Ramos; João T Guimarães; Nuno Borges
Journal:  Mol Genet Metab       Date:  2013-10-22       Impact factor: 4.797

Review 9.  Metabolism via Arginase or Nitric Oxide Synthase: Two Competing Arginine Pathways in Macrophages.

Authors:  Meera Rath; Ingrid Müller; Pascale Kropf; Ellen I Closs; Markus Munder
Journal:  Front Immunol       Date:  2014-10-27       Impact factor: 7.561

10.  Metabolomics of dietary fatty acid restriction in patients with phenylketonuria.

Authors:  Ulrike Mütze; Skadi Beblo; Linda Kortz; Claudia Matthies; Berthold Koletzko; Mathias Bruegel; Carmen Rohde; Joachim Thiery; Wieland Kiess; Uta Ceglarek
Journal:  PLoS One       Date:  2012-08-13       Impact factor: 3.240

View more
  5 in total

Review 1.  Oxidative stress in phenylketonuria-evidence from human studies and animal models, and possible implications for redox signaling.

Authors:  Vanessa Trindade Bortoluzzi; Carlos Severo Dutra Filho; Clovis Milton Duval Wannmacher
Journal:  Metab Brain Dis       Date:  2021-02-13       Impact factor: 3.584

2.  Lipid changes in the metabolome of a single case study with maple syrup urine disease (MSUD) after five days of improved diet adherence of controlled branched-chain amino acids (BCAA).

Authors:  Teresa D Douglas; L Kristin Newby; Julie Eckstrand; Douglas Wixted; Rani H Singh
Journal:  Mol Genet Metab Rep       Date:  2020-10-14

3.  Lower plasma cholesterol, LDL-cholesterol and LDL-lipoprotein subclasses in adult phenylketonuria (PKU) patients compared to healthy controls: results of NMR metabolomics investigation.

Authors:  Claire Cannet; Andrea Pilotto; Júlio César Rocha; Hartmut Schäfer; Manfred Spraul; Daniela Berg; Peter Nawroth; Christian Kasperk; Gwendolyn Gramer; Dorothea Haas; David Piel; Stefan Kölker; Georg Hoffmann; Peter Freisinger; Friedrich Trefz
Journal:  Orphanet J Rare Dis       Date:  2020-02-27       Impact factor: 4.123

4.  Plasma metabolomic profile changes in females with phenylketonuria following a camp intervention.

Authors:  Meriah S Schoen; Rani H Singh
Journal:  Am J Clin Nutr       Date:  2022-03-04       Impact factor: 7.045

Review 5.  Recent Advances in Understanding the Structure and Function of the Human Microbiome.

Authors:  Walaa K Mousa; Fadia Chehadeh; Shannon Husband
Journal:  Front Microbiol       Date:  2022-02-03       Impact factor: 5.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.